BioXcel Therapeutics (NASDAQ: BTAI) has crashed roughly 43% this regular-hours session after the biopharmaceutical company filed for Chapter 11 bankruptcy in the United States and simultaneously entered into an asset sale agreement with Teva Pharmaceuticals.
Why BTAI Is Plummeting Today
BioXcel Therapeutics filed for bankruptcy protection on August 28, 2026, according to reporting by Reuters, making it the latest casualty in a difficult environment for smaller biotech companies. The Connecticut-based firm, which employed just 37 people, also disclosed on the same day that it had entered into an asset sale agreement with Teva Pharmaceuticals. The combined impact of these disclosures sent shares into freefall during regular trading.
The bankruptcy filing caps a steep decline for the once-promising AI-driven drug development company. BTAI had previously faced headwinds including quarterly revenue misses and questions about the commercial trajectory of its flagship product, IGALMI (BXCL501), a sublingual film formulation of dexmedetomidine approved for acute agitation in adults with schizophrenia or bipolar disorder.
BTAI closed the prior day at $0.07. During this session, the stock dropped to $0.04, representing a 42.86% decline and erasing nearly all remaining shareholder value. Trading volume reached approximately 47.5 million shares, roughly 60 times the stock's average daily volume of under 800,000 shares, indicating extremely heavy selling pressure.
What We Know About the Teva Deal
GlobeNewsWire reported on August 28, 2026 that BioXcel entered into an asset sale agreement with Teva Pharmaceuticals. The terms and scope of that deal were not detailed in the available sources. Asset sale agreements in bankruptcy proceedings typically outline which assets will be sold, to whom, and under what conditions, with proceeds going toward satisfying creditor claims. The Teva agreement may represent the clearest path toward maximizing value from BioXcel's remaining assets, including its pipeline candidates and intellectual property.
Key Context: IGALMI and the Pipeline
Before the bankruptcy, BioXcel's lead commercial product was IGALMI, approved for in-clinic use. The company had been pursuing an at-home label expansion, with the FDA accepting a supplemental New Drug Application in April 2026. An at-home approval could have significantly expanded the market opportunity, but the bankruptcy filing now casts serious doubt on whether that launch will proceed under the current corporate structure.
The company had also been running clinical studies for BXCL501 in additional indications, including agitation associated with other conditions, and had enrolled the first patients in a U.S. Department of War-funded study for acute stress reactions.
Bottom Line
BTAI is trading at a penny-stock price of $0.04 with a market capitalization of roughly $1.24 million following a bankruptcy filing and an asset sale agreement with Teva Pharmaceuticals. The sharp 42.86% session drop reflects investors exiting positions as the company navigates Chapter 11 proceedings. The Teva deal may preserve some pipeline value, but shareholders face significant dilution or total loss in a reorganization scenario.